NL-OMON42420已完成3 期
Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis - CBYM338B2203E1
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Patients who completed the core study
- •- Written informed consent must be obtained before any extension study assessment is performed
- •- Able to communicate well with the investigator
- •- Willing to participate for the entire duration of the extension study with commitment to follow study requirements and procedures
排除标准
- •- Women who are pregnant
- •- Women of child-bearing potential unless they are using highly effective methods of contraception during dosing and for 6 months after the last BYM338 dose
- •- Current use of prohibited treatments
- •- History of severe hypersensitivity reaction in the core study
- •- History of adverse event(s) (including those from the core study) prior to the start of study drug in the extension study that, in the judgment of the investigator, taking into account the subject's overall status, prevent the subject from entering the extension study
- •- Clinically significant abnormal liver function tests
- •- Any medical condition or laboratory finding which, in the opinion of the investigator may interfere with participation in the study, might confound the results of the study, or pose an additional safety risk in administering BYM338
研究者
相似试验
进行中（未招募）
1 期
Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositisSporadic Inclusion Body MyositisEUCTR2015-001411-12-BEovartis Pharma Services AG240
进行中（未招募）
1 期
Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositisSporadic Inclusion Body MyositisEUCTR2015-001411-12-DKovartis Pharma Services AG240
进行中（未招募）
1 期
Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositisSporadic Inclusion Body MyositisEUCTR2015-001411-12-GBovartis Pharma Services AG211
进行中（未招募）
1 期
Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositisMedDRA version: 18.0Level: PTClassification code 10066407Term: Inclusion body myositisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSporadic Inclusion Body MyositisEUCTR2015-001411-12-FRovartis Pharma Services AG240
进行中（未招募）
1 期
Extension study to evaluate the long-term efficacy, safety and tolerabilityof BYM338 in patients with sporadic inclusion body myositisSporadic Inclusion Body MyositisEUCTR2015-001411-12-ITOVARTIS FARMA S.P.A.240